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Abstract
The purpose was to compare and comment on use of the SF-36 and MOS-HIV instruments in
studies of persons with HIV disease. Three medical information databases were searched to
identify examples of HIV studies that included the MOS-HIV or SF-36. Thirty-nine and 14 published
articles were identified for illustration in comparing the use of the MOS-HIV and SF-36 in HIV
disease, respectively. Support for the reliability and construct validity of the MOS-HIV and SF-36
was found. Ceiling and floor effects were reported for both the MOS-HIV and SF-36; however,
ceiling effects were more common for the MOS-HIV, in part due to fewer items in the physical,
social, and role functioning domains. The MOS-HIV measures three domains hypothesized to be
associated with the health deterioration of HIV disease not measured by the SF-36; however, these
domains may not assess aspects of HIV disease that typify the majority of the persons with HIV
disease today. National norms for the U.S. adult population (and other nations) are available for
the SF-36. In addition, the SF-36 has been used in a wide variety of patient populations, enabling
comparisons of HIV-infected persons with persons with other health conditions. No national
norms for the MOS-HIV are available. We conclude that there is currently insufficient evidence in
the literature to recommend the use of the MOS-HIV over the SF-36 in HIV-infected persons.
Although the SF-36 is not targeted at HIV, it may be preferable to use the SF-36 over the MOS-
HIV due to fewer ceiling effects, availability of national norms, and the vast amount of data for other
populations in the U.S. and around the world. Head-to-head comparisons demonstrating the
unique value of the MOS-HIV over the SF-36 are clearly needed. More importantly, additional work
needs to be directed at comparing the MOS-HIV and other putatively HIV-targeted instruments to
one another to help demarcate aspects of HRQOL that are truly generic versus specific to HIV
disease. Using both a generic and targeted HRQOL measure is a good general strategy, but this has
not been a typical practice in studies of HIV because the MOS-HIV is so similar in content to the
SF-36.
Introduction
Human immunodeficiency virus (HIV) and acquired
immune deficiency syndrome (AIDS) entered the public
consciousness over two decades ago. In the ensuing years,
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and well being, or health-related quality of life (HRQOL),
in HIV-infected individuals has been extensive [1–4].
While the treatment for HIV-infection remains non-cura-
tive, the improvements in mortality and AIDS-free sur-
vival for HIV-infected individuals have been substantial
[5,6]. The modification of the natural history of the dis-
ease with multi-pharmaceutical regimens that have
diverse beneficial as well as toxic effects [7] makes the
measurement of HRQOL in this patient population more
important than ever. However, there is no consensus
regarding the best measurement approach.
When a particular disease is being considered, there is a
tendency to assume that disease-targeted measures are
superior to general or generic measures. HIV/AIDS is no
exception. Numerous HIV/AIDS-targeted HRQOL meas-
ures have been developed. A recent review [8] evaluated
the psychometric properties of HIV disease-targeted
HRQOL instruments. Based on their review, the authors
could not recommend the use of any of the instruments
reviewed; however, the MOS-HIV was found to have the
most available evidence for the evaluation criteria
applied. Regardless of the lack of compelling arguments
for its use, the MOS-HIV appears to be the most popular
HRQOL instrument currently reported in the HIV litera-
ture. The purpose of this investigation is to examine the
use of the MOS-HIV, a measure targeted at HIV disease,
with the leading generic HRQOL instrument, the SF-36, in
studies of persons with HIV.
The Medical Outcomes Study
The Medical Outcomes Study (MOS) was a four-year
observational study that investigated the changes in phy-
sician practice styles and patient outcomes under different
healthcare settings such as health maintenance organiza-
tions, large physician groups, or individual physician fee-
for-service practices [9]. One of the goals of this longitudi-
nal study was to construct reliable and valid tools for
measuring and monitoring patient-reported functioning
and well-being [10]. To complement the conventional
clinical outcomes in the study, a spectrum of patient-
reported outcome measures was created [11].
The MOS Short Form 20-Item Health Survey (SF-20), a
brief, generic health status instrument that provides six
scale scores (general health perceptions, physical func-
tion, role function, social function, pain, and mental
health), was the first short form developed from the MOS
and was used for the screening of patients for chronic dis-
ease status during the cross sectional phase of the study
[11]. The SF-36, a second generation of the short form,
includes an additional health concept (energy/fatigue),
increases the precision of previous single-item measures
(pain, social functioning) and multi-item measures
(physical functioning) by adding additional items, meas-
ures the extent of physical limitations rather than the
duration of the limitation, and focuses on a wider array of
role limitations. The SF-36 was developed for the longitu-
dinal phase of the MOS. At least nine short form instru-
ments developed from the MOS scales have been used in
studies of HIV-infected persons [11]. Among those instru-
ments, the MOS-HIV has been reported to be the most
widely used by researchers in patients with HIV infection
[2,12,13].
Background to MOS-HIV and SF-36 Instruments
Owing to the perceived need for a succinct instrument to
evaluate HRQOL in HIV-infected patients in multi-center
AIDS clinical trials, the development of the MOS-HIV was
begun in 1987 [14]. Sixteen items selected from the six
scales of the SF-20 were the foundation for the construc-
tion of MOS-HIV. Four additional scales that were
hypothesized to be related to the health status of HIV-
infected persons (i.e., cognitive functioning [4 items],
energy/fatigue [4 items], health distress [4 items] and
quality of life [1 item]) as well as a single item assessing
health transition were added to the original scales in the
SF-20, resulting in a 30-item questionnaire [14]. The orig-
inal MOS-HIV included only one general health percep-
tion item. Subsequently, the 4 other SF-20 current health
items were added, leading to the 34-item MOS-HIV. With
the addition of a second pain item, the current version of
the MOS-HIV (distributed by the Medical Outcomes
Trust) contains 35 items. It covers 11 dimensions of
health including physical functioning, role functioning,
pain, social functioning, emotional well-being, energy/
fatigue, cognitive functioning, general health, health dis-
tress, overall QOL, and health transition. Mental (MHS)
and physical health summary (PHS) scores can be calcu-
lated from the MOS-HIV scales [15]. The MOS-HIV scales
range from 0 to 100, with higher scores representing bet-
ter functioning and well-being. The MHS and PHS are
scored using a method that transforms the scores to a
standardized scale (T score) with a mean of 50 and a
standard deviation of 10 in the sample in which the sum-
mary scores were developed [15]. Mean PHS and MHS
scores above or below 50 can be interpreted as having bet-
ter or worse HRQOL than the HIV-infected patient sample
from which the summary measures were developed.
The SF-36 is one of the most widely used HRQOL instru-
ments [16] and has demonstrated high levels of reliability
and validity in diverse patient populations [17,18]. It has
36 items that measure eight multi-item health concepts
(i.e., physical functioning, role-physical, bodily pain, gen-
eral health, vitality, social functioning, role emotional,
and mental health). This instrument was developed to
address the health-related concepts that are most influ-
enced by disease states and their related treatments [11].Page 2 of 7
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based component summary scores for mental and physi-
cal health. The mental (MCS-36) and physical component
summary (PCS-36) scores were derived from the eight
scales of the SF-36 using principal components analysis of
the total patient sample from the MOS and a sample of
the general US population [19]. These physical and men-
tal components account for 82% of the reliable variance
in the SF-36's scales in the general US population. The SF-
36 scales are scored on a 0 to 100 possible range, with
higher scores representing better functioning and well-
being. The MCS-36 and PCS-36 are scored using a method
that transforms the scores to a standardized scale (T-
scores) with a norm of 50 and a standard deviation of 10
in the general US population. Sample mean MCS-36 and
PCS-36 scores above or below 50 can be interpreted as
having better or worse HRQOL than the general US pop-
ulation. With norms established in subgroups based on
gender and age and thirty medical conditions, including
"healthy" with no chronic conditions, this standardized
scoring provides a means of comparing results across
patients with diverse medical conditions [20].
Examples of Studies of Persons with HIV using MOS-HIV or 
SF-36
A series of literature searches was performed to identify
studies that measured health status in persons with HIV
with the SF-36 or MOS-HIV. The literature in three data-
bases, Medline, HealthStar, and PsychInfo, was searched
from 1975 through 2002. The terms "quality of life,"
"HIV," and the name of the MOS instrument (i.e., SF-36
or MOS-HIV) were cross-referenced in each search of the
databases. Only articles written in English were included.
Discussion
Although other MOS-derived instruments have been
used, studies incorporating either the MOS-HIV or SF-36
were found to be the most prevalent in studies of HIV dis-
ease. Thirty-nine citations for the MOS-HIV were found
which presented empirical data [12,15,21–57]. Fourteen
empirical articles were found for the SF-36 [20,58–70]. At
the time of this review, more than 40 cross-cultural trans-
lations were available for the SF-36 and 14 translations for
the MOS-HIV [14,71]. Only the SF-36 and the SF-12 (a
subset of items from the SF-36 that reproduces > 90% of
the variance of the SF-36's summary scores) [19] have
norms available for their summary/composite measures
that have been calculated from nationally representative
samples.
Table 1 compares the numbers of items for each of the
scales of the MOS-HIV and SF-36. The SF-36 has four
additional items for the measurement of the physical
functioning domain (10 vs. 6), five more items for the role
functioning domains (7 vs. 2), and one more item for the
social functioning domain (2 vs. 1) than the MOS-HIV.
However, the MOS-HIV measures three domains (two
with multi-item scales [cognitive functioning and health
distress] and one with a single item [overall quality of
life]) that are not measured by the SF-36.
The two instruments take about five to ten minutes to be
self-administered and can be interviewer administered in
person or by telephone [48]. Reliability has been sup-
ported for the MOS-HIV [14,15]and the SF-36 [20,59,72].
in this patient population. Support for item discrimina-
tion of the MOS-HIV has been shown in comparison with
other HIV-targeted and generic HRQOL instruments [14].
One study found no differences in health distress and
quality of life scale scores of the MOS-HIV in patients with
early vs. late stages of HIV disease [12]. Differences have
been found between HIV-infected and non-infected per-
sons on all scales of the SF-36 [66] while only the sum-
mary scores of MOS-HIV distinguished between these two
groups [22,23]. The physical health summary scores from
the SF-12 and the MOS-HIV both have been found to dis-
Table 1: Number of items in the scales of the MOS-HIV and SF-36.
Scale MOS-HIV SF-36
Physical functioning 6 10
Role functioning 2 7
Pain 2 2
Social functioning 1 2
Emotional well-being 5 5
Energy / fatigue 4 4
Cognitive functioning 4 0
General health 5 5
Health distress 4 0
Overall QoL 1 0
Health transition 1 1Page 3 of 7
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200 CD4 t-cell counts [32,73].
The summary scores of the SF-36 have been shown to be
responsive to HIV disease progression [20,74]. The MOS-
HIV has been useful in illustrating changes in clinical sta-
tus between treatment and control groups in intervention
and observational studies; however, the role functioning,
pain, mental health, health distress, and quality of life
scales were shown to be non-responsive to treatment in
one anti-retroviral intervention study [29]. Ceiling effects
have been found for the physical functioning, role func-
tioning and role emotional scales of the SF-36 [60] and
MOS-HIV [37,55]. Ceiling effects have been found in the
cognitive functioning, pain, and health transition scales of
the MOS-HIV in HIV-infected patients with more
advanced HIV disease [35]. In addition, the role function-
ing scale of the MOS-HIV has been found to have floor
effects in HIV-infected patients with more advanced HIV
disease [21,22,35,37].
Conclusions
One of the primary distinctions between the MOS-HIV
and the SF-36 is the availability of nationally representa-
tive norms for the SF-36. Mental and physical health sum-
mary scores can be calculated for the MOS-HIV, but
norms for these scores are available from only the subjects
in the studies from which they were developed. The avail-
ability of nationally representative normative data per-
mits the comparison of summary scores from one
individual or a group of study subjects with scores from a
sample representative of the general population. In addi-
tion, nationally representative norms for the MCS-36 and
PCS-36 summary scores are available for males and
females in seven age groups and for fourteen chronic con-
ditions [75]. These norms permit healthcare decision
makers to utilize the summary scores from the SF-36 to
compare the health status of HIV-infected persons with
other persons of similar gender and age, or with another
chronic condition.
Perceived health of asymptomatic HIV-infected individu-
als does not appear to vary much from non-infected sub-
jects. Wu and colleagues [76] demonstrated that HRQOL
in HIV-infected patients with no symptoms or significant
abnormalities was not different from that of healthy non-
infected individuals. In a more recent study, Hays and col-
leagues found that the physical functioning of asympto-
matic HIV-infected subjects was similar to that of the
general US population [74]. In addition to increased
measurement precision, using the SF-36 in patients in the
early stages of HIV disease would allow a researcher to
compare and contrast the health status of these HIV-
infected individuals with the health status of patients with
diverse chronic conditions in a range of cultures.
While the MOS-HIV has demonstrated evidence of relia-
bility, construct validity and responsiveness among HIV-
infected patient subjects, [12,15,42,43,77] there are limi-
tations to the instrument. To allow for the addition of
"disease-targeted" scales while not increasing respondent
burden, the developers of the MOS-HIV sacrificed some
measurement precision for the physical functioning,
social functioning, and role functioning scales by reduc-
ing the number of items [21,24,35,37]. These scales, in
particular, appear to be important in assessing HRQOL in
this patient population since the majority of the persons
infected with HIV are young adults who are still function-
ing normally in society and may not perceive themselves
as having functional impairment [13,37]. For example,
the full-length 10-item physical functioning scale of the
SF-36 allows for the sampling of a wider range of severe
and minor physical limitations and may provide for a bet-
ter representation of the levels and types of physical limi-
tations in this population [18]. The decreased
measurement precision of the functioning scales in the
MOS-HIV may explain why ceiling and floor effects have
been found in a number of studies. Ceiling and floor
effects become problematic when patients in longitudinal
studies score the lowest or highest possible score at the
baseline since subjects then can not report any lower or
higher score that may occur if their health status deterio-
rates or improves at follow-up [78].
The MOS-HIV was developed over a decade ago when HIV
disease and its treatment were very different from today
[79]. At that time, rapid health deterioration from HIV
disease and its associated sequelae was prevalent. With
rapid progression into the late stages of HIV disease, mon-
itoring the HRQOL of patients who were developing HIV-
infection associated sequelae such as cancers (e.g.,
Kaposi's sarcoma), opportunistic infections (e.g., pneu-
mocystis carinii pneumonia), and AIDS dementia was
imperative. The disease-targeted scales (i.e., cognitive
functioning, health distress, and quality of life) added to
the 16 items from the SF-20 to develop the MOS-HIV were
included in the instrument to measure domains hypothe-
sized to be associated with the HIV disease-related health
deterioration [12]. Currently, however, with the availabil-
ity of HAART, HIV disease is, for the majority of patients,
a chronic rather than acute condition [79] and, as such,
may require an instrument to assess HRQOL that was
designed for chronic rather than acute diseases. Indeed,
empirical evidence supporting the construct validity of the
disease-targeted scales of the MOS-HIV is limited [12].
The current chronic nature of the disease may preclude the
necessity to monitor the HIV disease-targeted domains of
the MOS-HIV in the general population of HIV-infected
patients. Nevertheless, if monitoring of HIV disease-tar-
geted health concepts is important, the MCS-36 summaryPage 4 of 7
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functioning (r = 0.70) and quality of life (r = 0.68) scales
and negatively correlated with the health distress (r = -
0.57) scale of the MOS-HIV [75]. This indicates that the
MCS-36 represents these health concepts to some degree.
Furthermore, in populations of patients in the late stages
of HIV disease, augmenting the SF-36 with additional
scales or instruments targeting the specific consequences
of the disease and its treatment may be an effective
approach. Two abstracts presented at the 1996 Interna-
tional Conference on AIDS found that the addition of HIV
disease-targeted scales to the SF-36 did not detract from
the measurement precision of the SF-36-specific scales or
increase response burden appreciably and did provide for
the effective monitoring of HIV disease [80,81].
Our results were based on studies identified through sev-
eral databases. There are other databases that may have
contained studies that were not included in our evalua-
tion. In addition, there were only 14 studies identified
that utilized the SF-36 in HIV-infected persons. It is possi-
ble that additional studies are needed to more fully docu-
ment the strengths and shortcomings of this instrument.
In sum, this study revealed that although the MOS-HIV
has been used widely in the monitoring of HIV-infected
persons, it has noteworthy limitations that may constrain
its applications in this population. Hence, there is insuffi-
cient evidence in the literature to support the use of the
MOS-HIV rather than the SF-36 in HIV-infected persons.
Although the SF-36 is not targeted at HIV, it may be pref-
erable to use the SF-36 over the MOS-HIV due to fewer
ceiling effects, availability of national norms, and the vast
amount of data for other populations in the U.S. and
around the world. Head-to-head comparisons demon-
strating the unique value of the MOS-HIV over the SF-36
are clearly needed. In addition, more work needs to be
directed at comparing the MOS-HIV and other putatively
HIV-targeted instruments to one another to help demar-
cate aspects of HRQOL that are truly generic versus spe-
cific to HIV disease.
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